Dr Carlos Barrios was born in Uruguay and graduated from PUCRS, Porto Alegre, RS, Brazil in 1979. He is an Adjunct Assistant Professor of the William Harrington Latin American Program at the University of Miami School of Medicine.

He has been the Director and Principal Investigator of the Oncology Research Center at Hospital São Lucas, PUCRS since 1996, where he has participated in over 250 clinical research trials over the last few years.

He is Director of Clinical Research and Oncologist of the Oncoclínicas Group in Porto Alegre. Currently, he is also a member and serves on the Executive Board of the Breast International Group (BIG).

He has a strong interest in the development of international research collaboration and the implementation of cooperative research infrastructures in Latin America. As such, he is co-founder and current President of LACOG (Grupo Latino Americano de Investigación Clínica en Oncologia – Latin American Clinical Oncology Research Group) which congregates more than 200 investigators, more than 70 institutions in 16 different countries in Latin America.

Has formal training and certification in the areas of Internal Medicine (Hospital de Clínicas, UFRGS, Porto Alegre, Brazil (1980-1982) and Jackson Memorial Hospital, University of Miami, Miami, Fl, US (1982-1985). He also has formal training and certification (ABIM) in Hematology and Oncology at Barnes and Jewish Hospitals, Washington University, Saint Luis, MO, US (1985-1988).

He is a member of several professional and research organizations, such as ASCO (American Society of Clinical Oncology), ESMO (European Society of Medical Oncology), AACR (American Association for Cancer Research), SBOC (Sociedade Brasileira de Oncologia Clínica – Brazilian Society of Clinical Oncology), GBECAM (Grupo Brasileiro de Estudos no Câncer de Mama – Brazilian Breast Cancer Group), GBOT (Grupo Brasileiro de Oncologia Torácica – Brazilian Group of Thoracic Oncology), IASL (International Association for the Study of Lung Cancer).

His clinical work has been concentrated in the area of Breast Cancer.  Has participated in numerous clinical research projects and has numerous abstract presentations and scientific peer-reviewed publications. He was included in the list of Highly Cited Researchers 2023 (Clarivate), ranking in the top 1% by citations in the field.